Arkolith/Insider Trading/CADL/Form 4

Manning Paul B

DirectorCandel Therapeutics, Inc. (CADL) · full profile →Form 4 · filed Feb 26, 2026
Net Buying
Open-Market Buys
$3.0M
Open-Market Sells
$0
Net Open-Market Flow
$3.0M
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 23, 2026Buy(P)550K$5.45$3.0M2.8M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-078246) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML